Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Convention 2025 Transcript

Yuxi Dong
Jefferies LLC, Analysis Division

All proper. Let’s get began, and good afternoon, everybody. Thanks for becoming a member of us for Jefferies London Healthcare Convention. My identify is Clara Dong, one of many biotech analysts right here at Jefferies. So it is my absolute pleasure to welcome Dr. Lawrence Blatt, CEO of Aligos Therapeutics, to present us a presentation right here. Welcome.

Lawrence Blatt
CEO, President & Chairman of the Board

Thanks, and thanks to the Jefferies crew for inviting us to current as we speak. I’ll stroll via our portfolio at Aligos as we speak. And whereas doing that, I am going to make some forward-looking statements. So we now have a big Section II pipeline at Aligos. Our lead program is in hepatitis B. The molecule known as pevifoscorvir. We name it pevi. Beforehand, you may need heard of ALG-184. I am going to discuss lots about that molecule as we speak. Along with that, we now have a drug — purpose-built beta thyroid agonist, ALG-009. That is accomplished Section IIa testing. I am going to discuss just a little bit in regards to the outcomes there in addition to some preclinical outcomes we now have in weight problems.

We — along with these molecules, we now have a protease inhibitor for coronavirus. It is a pan-coronavirus protease inhibitor. And proper now, right here within the U.Ok., it is present process a Section II research that is being funded by the MRC. Along with that, in our preclinical portfolio, we now have an antisense oligonucleotide focusing on hepatitis B virus in addition to an antisense oligonucleotide focusing on hepatitis delta virus. So I’ll dig deeper into continual HBV an infection. I believe most individuals know that HBV is the biggest continual viral an infection on the planet that causes